Profile data is unavailable for this security.
About the company
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
- Revenue in USD (TTM)39.41bn
- Net income in USD3.16bn
- Incorporated1999
- Employees70.21k
- LocationGSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
- Phone+44 208 047 5000
- Fax+44 208 047 7807
- Websitehttps://www.gsk.com/
Mergers & acquisitions
| Acquired company | GSK:LSE since announced | Transaction value |
|---|---|---|
| Aiolos Bio Inc | -13.90% | 1.40bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty Pharma plc | 2.27bn | 1.15bn | 15.55bn | 89.00 | 10.32 | 2.27 | 21.68 | 6.86 | 2.56 | 2.56 | 3.80 | 11.63 | 0.1337 | -- | 72.15 | 25,460,710.00 | 10.11 | 9.57 | 13.30 | 12.42 | -- | -- | 75.64 | 67.80 | -- | -- | 0.4258 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
| Viatris Inc | 15.05bn | -883.30m | 15.82bn | 38.00k | -- | 0.799 | 8.29 | 1.05 | -0.7389 | -0.7389 | 12.54 | 16.58 | 0.3219 | 2.23 | 4.94 | 396,013.20 | -1.89 | 0.0887 | -2.23 | 0.1061 | 42.49 | 40.29 | -5.87 | 0.2891 | 0.9615 | 2.37 | 0.443 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Biogen Inc | 9.61bn | 1.62bn | 23.03bn | 7.57k | 14.28 | 1.40 | 10.17 | 2.40 | 11.07 | 11.07 | 65.83 | 112.90 | 0.34 | 0.8604 | 4.58 | 1,269,155.00 | 5.71 | 12.53 | 7.01 | 14.83 | 75.59 | 83.04 | 16.80 | 26.93 | 0.8039 | 4.89 | 0.2778 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| Alnylam Pharmaceuticals, Inc. | 2.09bn | -332.26m | 31.83bn | 2.10k | -- | 982.81 | -- | 15.20 | -2.62 | -2.62 | 16.52 | 0.2511 | 0.5208 | 3.57 | 8.41 | 997,521.40 | -8.26 | -26.56 | -11.31 | -32.77 | 85.37 | 83.66 | -15.86 | -94.26 | 2.69 | -1.36 | 0.9694 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| GSK plc (ADR) | 39.41bn | 3.16bn | 68.66bn | 70.21k | 21.97 | 3.90 | 9.72 | 1.74 | 1.53 | 1.53 | 19.18 | 8.64 | 0.5266 | 1.51 | 3.93 | 561,274.50 | 4.79 | 6.74 | 7.48 | 10.71 | 72.44 | 70.29 | 9.10 | 16.93 | 0.5303 | 13.08 | 0.5442 | 79.55 | 3.42 | -0.322 | 15.79 | 7.10 | 5.47 | -- |
| Zoetis Inc | 9.15bn | 2.43bn | 79.73bn | 14.10k | 33.22 | 15.25 | 27.14 | 8.71 | 5.32 | 5.32 | 20.02 | 11.59 | 0.6431 | 1.06 | 6.86 | 649,078.00 | 17.13 | 14.47 | 19.38 | 17.18 | 70.13 | 69.77 | 26.64 | 25.77 | 2.27 | 18.96 | 0.5567 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 30 Sep 2024 | 68.09m | 3.29% |
| JTC Plc /Private Banking/as of 30 Sep 2024 | 20.48m | 0.99% |
| Fisher Asset Management LLCas of 30 Sep 2024 | 18.58m | 0.90% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 14.85m | 0.72% |
| Strategic Advisers LLCas of 30 Sep 2024 | 12.85m | 0.62% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 12.79m | 0.62% |
| T. Rowe Price International Ltd.as of 30 Sep 2024 | 7.53m | 0.36% |
| Goldman Sachs Asset Management LPas of 30 Sep 2024 | 7.08m | 0.34% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 6.78m | 0.33% |
| RBC Capital Markets LLC (Investment Management)as of 30 Sep 2024 | 5.88m | 0.28% |
